Device Trial Radar · NCT06098937
Kalifilcon A Toric Compared to Commercially Available Lenses
Last checked: Nov 20, 2026Latest source record: Dec 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Sep 5, 2023
Primary completion
Sep 27, 2023
Study completion Sep 27, 2023
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedNot on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 25, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Approximately thirty contact lens adapted subjects will be enrolled in this feasibility, bilateral, randomized, double masked (subject and investigator masked), repeated measures insertion study.
Conditions
- Astigmatism
Interventions
Kalifilcon Toric LensDevice
Kalifilcon A Daily Disposable Toric for Ametropia
Total1 for AstigmatismDevice
Total1 for Astigmatism
Precision1 for AstigmatismDevice
Precision1 for Astigmatism
MyDay ToricDevice
MyDay Toric
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Gaze Orientation for 5 MinutesTime frame: 5 minutes after lens insertion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bausch & Lomb, Incorporated
Rochester, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.